resistant/refractory to r/r to HMA
Showing 1 - 25 of >10,000
Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
-
Shanghai, Shanhai, ChinaRuijin Hospital
Sep 29, 2023
B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- HY004
- +2 more
- (no location specified)
Aug 18, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)
Recruiting
- Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
- thiotepa combined with pomalidomide
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital.
Jun 27, 2023
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)
Not yet recruiting
- Refractory Multiple Myeloma
- +2 more
-
Boston, Massachusetts
- +2 more
Nov 17, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Anti-GPRC5D CAR-T Cells Injection
- (no location specified)
Feb 18, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)
Recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Anti-GPRC5D CAR-T cells infusion
-
Kunming, Yunnan, China
- +1 more
Feb 21, 2023
AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))
Not yet recruiting
- AML, Adult
- Pharmacoscopy
- Clinical standard-of-care (physician's choice)
- (no location specified)
Nov 20, 2023
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)
Not yet recruiting
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
- (no location specified)
Sep 25, 2023
Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)
Recruiting
- Marginal Zone Lymphoma
- Obinutuzumab, lenalidomide
-
Tianjin, Tian, ChinaInstitute of Hematology & Blood Diseases Hospital
Apr 27, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Mar 23, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma
-
Kaohsiung, Taiwan
- +4 more
Apr 17, 2023
Leukemia, Lymphoid Trial in Chengdu (blinatumomab)
Not yet recruiting
- Leukemia, Lymphoid
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Oct 3, 2023
Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)
Recruiting
- Acute Myeloid Leukemia
- CLL1 and CD38 dual-target CAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023
B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- single dose of CNCT19
- (no location specified)
Dec 19, 2022
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed/Refractory Marginal Zone Lymphoma
- Orelabrutinib
- +3 more
-
Guangzhou, Guangdong, China
- +10 more
Oct 8, 2023
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States
Completed
- Non-Hodgkin's Lymphoma, Relapsed
- +8 more
- PBCAR20A
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Dalpiciclib Isetionate Tablets, Camrelizumab
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023